Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analysts following Alterity Therapeutics know that every SEC release can shift the outlook for ATH434鈥檚 Parkinsonian trials. Whether you need the latest Alterity Therapeutics quarterly earnings report 10-Q filing to gauge cash runway, or want to monitor Alterity Therapeutics insider trading Form 4 transactions before pivotal data, this page covers the entire journey.
Stock Titan鈥檚 AI instantly converts dense 10-Ks into concise, plain-English overviews鈥攑erfect when you鈥檙e understanding Alterity Therapeutics SEC documents with AI instead of wading through scientific jargon. Set real-time alerts for Alterity Therapeutics Form 4 insider transactions, scan 8-K material events explained for fresh clinical results, or dive into the proxy statement executive compensation tables without scrolling hundreds of pages.
Each filing type answers a different biotech question: 10-Qs reveal R&D burn and trial milestones; 10-Ks provide a lab-to-market road map in one place鈥攁n Alterity Therapeutics annual report 10-K simplified. Curious about board decisions? The Alterity Therapeutics proxy statement executive compensation breaks down incentives tied to ATH434 progress. Want color on collaborations or sudden capital raises? An Alterity Therapeutics 8-K material events explained section flags them the moment they hit EDGAR. All documents are indexed, searchable, and paired with AI-powered summaries so you can compare quarter-over-quarter results, track Alterity Therapeutics earnings report filing analysis, and spot Alterity Therapeutics executive stock transactions Form 4 patterns鈥攆aster than ever. Make smarter biotech decisions with complete, real-time coverage designed for professionals who can鈥檛 afford to miss a single disclosure.
Alterity Therapeutics (ATHE) is a development鈥憇tage biopharmaceutical group focused on neurodegenerative diseases, notably ATH434 for Multiple System Atrophy (MSA). The company reported a net loss of A$12.15 million for the year and recorded a A$5.44 million R&D tax incentive as other income. Cash and cash equivalents increased to A$33.16 million at June 30, 2025, supported by significant equity raises including a placement of 3.636 billion shares at A$0.011 and issuance of 1.222 billion listed long鈥慸ated options. Multiple patents (including composition of matter for ATH434) have been granted in several jurisdictions; one U.S. patent lists expiry June 7, 2026. Clinical and conference activity in 2024鈥�2025 includes Phase 2 ATH434 data presented at major neurology meetings. The company continues to disclose material risks: ongoing operating losses, need for further financing, clinical development and manufacturing risks, intellectual property challenges, and NASDAQ listing and PFIC considerations.
FAQ
What is the current stock price of Alterity Therapeutics (ATHE)?
What is the market cap of Alterity Therapeutics (ATHE)?
